Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.

Authors:
Abdulhaq H; Hwang A; Mahmood O.

Journal:
Onco Targets Ther

Publication Year: 2023

DOI:
10.2147/OTT.S372783

PMCID:
PMC10364833

PMID:
37492075

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Onco Targets Ther

Abbreviation: Onco Targets Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Applications of Yttrium-90 (<sup>90</sup>Y) in Hepatocellular Carcinoma.
Jiang Z; Yang F; Wang W. (2024) - Transparency Score: 3/6
Crosstalk Between circRNA and Tumor Microenvironment of Hepatocellular Carcinoma: Mechanism, Functi…
Xie C; Hao X; Yuan H and 3 more (2024) - Transparency Score: 3/6
Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clin…
Zhang Y; Wan W; Shen R and 6 more (2024) - Transparency Score: 3/6
TSC22D2 Regulates ACOT8 to Delay the Malignant Progression of Colorectal Cancer.
Zhou N; Guo C; Du J and 4 more (2024) - Transparency Score: 3/6
Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Directi…
Buller DM; Antony M; Ristau BT. (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Dr Haifaa Abdulhaq reports grants, personal fees from Morphosys, personal fees from Novartis, personal fees from BMS, grants from Genentech, personal fees from Amgen, personal fees from AbbVie, outside the submitted work. The authors report no other conflicts of interest in this work."

Evidence found in paper:

"Disclosure: Dr Haifaa Abdulhaq reports grants, personal fees from Morphosys, personal fees from Novartis, personal fees from BMS, grants from Genentech, personal fees from Amgen, personal fees from AbbVie, outside the submitted work. The authors report no other conflicts of interest in this work."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025